Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)

Protocol: BMT-CTN1102

Full Title

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome


This study is designed as a multicenter trial, with biological assignment to one of two

study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell

transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.

Study Objective

Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may

evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for

researchers, clinicians, patients, and health care underwriters such as Medicare, is the

role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older

patients with higher risk myelodysplastic syndromes (MDS). The use of reduced intensity

conditioning (RIC) regimens has extended HCT to the care of older patients with acute

myelogenous leukemia (AML) and lymphoma and a number of retrospective and phase II trials

for patients with MDS now show the curative potential of RIC alloHCT in selected patients.

This protocol is designed to evaluate the relative benefits of RIC alloHCT compared to

non-transplant therapies focusing on overall survival. This will be done by having patients

biologically assigned to the alloHCT arm or the hypomethylating therapy/best supportive care

arm and following them for survival at 3 years.

Are you eligible?

Inclusion Criteria:

Patients fulfilling the following criteria will be eligible for entry into this


1. Patients with de novo MDS who have, or have previously had, Intermediate-2 or

High risk disease as determined by the International Prognostic Scoring System

(IPSS). Current Intermediate-2 or High risk disease is NOT a requirement.

2. Patients must have an acceptable MDS subtype:

Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory

anemia (RA))

Refractory anemia with ringed sideroblasts (RARS)

Refractory anemia with excess blasts (RAEB-1)

Refractory anemia with excess blasts (RAEB-2)

Refractory cytopenia with multilineage dysplasia (RCMD)

Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)

Myelodysplastic syndrome (MDS), unclassifiable

3. Patients must have fewer than 20% marrow blasts within 60 days of consent.

4. Patients may have received prior therapy for the treatment of MDS, including but

not limited to: growth factor, transfusion support, immunomodulatory (IMID)

therapy, DNA hypomethylating therapy, or cytotoxic chemotherapy prior to


5. Age 50.0-75.0 years.

6. Karnofsky performance status > 70 or Eastern Cooperative Oncology Group (ECOG) ≤


7. Patients are eligible if no formal unrelated donor search has been activated

prior to date of consent. A formal unrelated donor search begins at the time at

which samples are requested from potential National Marrow Donor Program (NMDP)

donors. Patients who have started a sibling donor search or who have found a

matched sibling donor are eligible.

8. Patients and physicians must be willing to comply with treatment assignment:

1. No intent to proceed with alloHCT using donor sources not specified in this

protocol, including human leukocyte antigen (HLA)-mismatched related or

unrelated donors (< 6/6 HLA related matched or < 8/8 HLA unrelated matched)

or umbilical cord blood unit(s).

2. No intent to use myeloablative conditioning regimens.

3. Intent to proceed with RIC alloHCT if a matched sibling or matched

unrelated donor is identified. There is no requirement as to the timing of

the transplantation.

9. Patients must be considered to be suitable RIC alloHCT candidates at the time of

enrollment based on medical history, physical examination, and available

laboratory tests. Specific testing for organ function is not required for

eligibility but, if available, these tests should be used to judge eligibility.

10. Signed informed consent

Exclusion Criteria:

Patients with the following will be ineligible for registration onto this study:

1. Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to

systemic chemotherapy and/or radiation for malignancy)

2. Current or prior diagnosis of AML

3. Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm

(unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection

(currently taking medication and with progression or no clinical improvement) at

time of enrollment.

4. Patients with prior malignancies, except treated non-melanoma skin cancer or

treated cervical carcinoma in situ. Cancer treated with curative surgery without

chemotherapy/radiation therapy > 5 years previously will be allowed. Cancer

treated with curative surgery < 5 years previously will not be allowed unless

approved by the Protocol Officer or one of the Protocol Chairs.

5. Prior autologous or allogeneic HCT

6. Human Immunodeficiency Virus (HIV) infection

7. Patients of childbearing potential unwilling to use contraceptive techniques

8. Patients with psychosocial conditions that would prevent study compliance

Myelodysplastic Syndrome Leukemia